Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pacira Pharmaceuticals, Inc. on January 3, 2019. The filing serves to announce preliminary unaudited net product sales for the company's flagship product, EXPAREL, for the fourth quarter and the full year ended December 31, 2018.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release (Exhibit 99.1) containing the preliminary sales figures for EXPAREL, but the specific dollar amounts are not included in the body of this 8-K document.
Material Changes
The filing does not contain comparative data or analysis of material changes versus prior periods within the text provided. It solely acts as a notification that preliminary sales data for the 2018 period has been released.
Guidance, Outlook, and Risks
The document does not contain forward-looking guidance, management commentary on future outlook, or specific risk factors. It includes a standard disclaimer stating that the information in Item 2.02 and the attached press release is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated January 3, 2019) for the specific EXPAREL net product sales figures for Q4 and full-year 2018.
- Verify the unaudited nature of the reported sales data.
- Check subsequent filings (e.g., 10-K) for the audited financial statements and detailed reconciliation of the preliminary data.